The present and future of prostate cancer urine biomarkers

Marina Rigau, Mireia Olivan, Marta Garcia, Tamara Sequeiros, Melania Montes, Eva Colás, Marta Llauradó, Jacques Planas, Inés de Torres, Juan Morote, Colin Cooper, Jaume Reventós, Jeremy Clark, Andreas Doll

Research output: Contribution to journalArticlepeer-review

37 Citations (Scopus)

Abstract

In order to successfully cure patients with prostate cancer (PCa), it is important to detect the disease at an early stage. The existing clinical biomarkers for PCa are not ideal, since they cannot specifically differentiate between those patients who should be treated immediately and those who should avoid over-treatment. Current screening techniques lack specificity, and a decisive diagnosis of PCa is based on prostate biopsy. Although PCa screening is widely utilized nowadays, two thirds of the biopsies performed are still unnecessary. Thus the discovery of non-invasive PCa biomarkers remains urgent. In recent years, the utilization of urine has emerged as an attractive option for the non-invasive detection of PCa. Moreover, a great improvement in high-throughput "omic" techniques has presented considerable opportunities for the identification of new biomarkers. Herein, we will review the most significant urine biomarkers described in recent years, as well as some future prospects in that field.
Original languageEnglish
Pages (from-to)12620-49
Number of pages30
JournalInternational Journal of Molecular Sciences
Volume14
Issue number6
DOIs
Publication statusPublished - 2013

Cite this